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PD98059Parthanatos is a programmed necrotic demise characteristic of ATP (adenosine triphosphate) consumption due
to NAD+ (nicotinamide adenine dinucleotide) depletion by poly(ADP-ribose) polymerase 1 (PARP1)-dependent
poly(ADP-ribosyl)ation on target proteins. However, how the bioenergetics is adaptively regulated during
parthanatos, especially under the condition of macroautophagy deﬁciency, remains poorly characterized. Here,
we demonstrated that the parthanatic inducer N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) triggered ATP de-
pletion followed by recovery in mouse embryonic ﬁbroblasts (MEFs). Notably, Atg5−/−MEFs showed great sus-
ceptibility to MNNG with disabled ATP-producing capacity. Moreover, the differential energy-adaptive
responses inwild-type (WT)andAtg5−/−MEFswere unequivocallyworsened by inhibition of AMP-activated pro-
tein kinase (AMPK), sirtuin 1 (SIRT1), andmitochondrial activity. Importantly, Atg5−/−MEFs disclosed diminished
SIRT1 and mitochondrial activity essential to the energy restoration during parthanatos. Strikingly, however,
parthanatos cannot be exasperated by baﬁlomycin A1 and MNNG neither provokes microtubule-associated pro-
tein 1A/1B-light chain 3 (LC3) lipidation and p62 elimination, suggesting that parthanatos does not induce autoph-
agic ﬂux. Intriguingly, we reported unexpectedly that PD98059, even at low concentration insufﬁcient to inhibit
MEK, can promote mitochondrial activity and facilitate energy-restoring process during parthanatos, without
modulating DNA damage responses as evidenced by PARP1 activity, p53 expression, and γH2AX (H2A histone
family, member X (H2AX), phosphorylated on Serine 139) induction. Therefore, we propose that Atg5 deﬁciency
confers an inﬁrmity to overcome the energy crisis during parthanatos and further underscore the deﬁcits in mito-
chondrial quality control, but not incapability of autophagy induction, that explain the vulnerability in Atg5-
deﬁcient cells. Collectively, our results provide a comprehensive energy perspective for an improved treatment
to alleviate parthanatos-related tissue necrosis and disease progression and also provide a future direction for
drug development on the basis of PD98059 as an efﬁcacious compound against parthanatos.
© 2013 Elsevier B.V. All rights reserved.1. IntroductionParthanatos is a particular type of programmed necrosis charac-
terized by the death signal poly(ADP-ribose) (PAR) polymers,
poly(ADP-ribose) polymerase (PARP)-mediated PAR accumulation,
ATP and NAD+ depletion, mitochondrial perturbation, and apoptosis-
inducing factor (AIF) nuclear translocation from mitochondria [1–4].7-aminoactinomycin D; AIF,
kinase; DPI, diphenyliodonium;
; FCCP, triﬂuorocarbonylcyanide
A/1B-light chain 3; LDH, lactate
ase; MEFs, mouse embryonic
e; mtDNA, mitochondrial DNA;
AR, poly(ADP-ribose); PARP1,
rator-activated receptor (PPAR)
, Taipei, Taiwan. Tel.: +886 2
).
respondence.
ights reserved.Among all PARP superfamily, PARP1 is the most abundant protein
localized in the nucleus that could immediately respond to the
DNA damage, such as alkylation or double-strand breaks, to promote
DNA repair machinery through NAD+-dependent PARylation on accep-
tor proteins, such as histones and PARP1 itself [5,6]. However, if the
DNA damage is irreparable, PARP1 over-activation will culminate in
PARP1-dependent parthanatic cell death. Widespread as an environ-
mental mutagen, N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) is
such a commonly used DNA-alkylating agent that potently initiates
parthanatic cell death in a caspase-independent manner [3]. In our
previous study, we have conﬁrmed that MNNG is able to induce AIF
nuclear translocation and necrotic cell death in mouse embryonic
ﬁbroblasts (MEFs) [7]. Moreover, the cell death was prevented by
PARP1 inhibitors such as 3-aminobenzamide (3AB) and 3,4-dihydro-5
[4-(1-piperindinyl) butoxy]-1(2H)-isoquinoline (DPQ), implicating
MNNG-induced cell death due to PARP1 over-activation [7].
Parthanatos has been implicated in several pathological condi-
tions, such as neurodegenerative disorders including Parkinson's
and Alzheimer's diseases, glutamate excitotoxicity, stroke, ischemia–
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spent to understand this distinct type of cell death to hinder from exten-
sive tissue inﬂammation and disease progression [12]. Besides several
parthanatic hallmarks already deﬁned [2], mitogen-activated protein
kinase (MAPK) signaling pathways such as JNK and p38 have also been
implied to regulate the parthanatic responses [13,14]. Considering
the energy depletion as an essential biochemical feature, enforced reple-
tion of metabolic intermediates has been utilized to prevent from
parthanatic cell death in neurons and astrocytes [15,16]. Despite the
current progress in our understandings about parthanatos, the need
for efﬁcacious PARP inhibitors of better therapeutic potential is emerg-
ing [17]. Currently, the crystal structure of a DNAdouble-strand break in
complexwith human PARP1 domains obligatory for activation has been
resolved [18], which may facilitate the process in designing novel
PARP1 inhibitors.
Macroautophagy (hereafter termed autophagy) is highly coordi-
nated self-digesting process involving autophagosomal engulfment
and lysosomal degradation of damaged proteins or organelles for
recycling to maintain intracellular energy homeostasis under normal
physiological condition or in response to certain stress stimuli [19,20].
Derangement of autophagy has a pathogenic contribution to several
diseases, like infection, cancer, neurodegeneration, heart diseases, and
aging [21–25].
Currently, however, less is known about the regulation of energy
turnover during parthanatos. Considering autophagy is a self-protective
scheme in response to stress for energy preservation and parthanatos
is a cell death process associated with energy depletion, we were inter-
ested in understanding the role of autophagy in energy regulation during
parthanatos. Moreover, inspired by the concomitant occurrences of
autophagy dysregulation and parthanatos in neurodegenerative and
cardiovascular disorders, we speculated that autophagy defects
may amplify the severity of parthanatic cell death. In this study,
we tried to elucidate the contribution of autophagy dependency as well
as the elsewhere mentioned MAPK pathways to energy homeostasis
and severity during parthanatos in MEFs. Here, we demonstrate for the
ﬁrst time that Atg5−/− MEFs are extremely susceptible to MNNG and
that PD98059, a traditionally knownMEK inhibitor, shows an unexpect-
ed protectiveness and saves the vulnerableMEFs during parthanatos in a
MEK-independent manner. On the other hand, we also highlight the
indispensable roles of AMP-activated protein kinase (AMPK), sirtuin 1
(SIRT1), and mitochondrial activity in regulating energy restoration
during parthanatos, which also better explain the differential
response in Atg5-deﬁcient cells. Collectively, these results provide
a complete energy perspective for better treating parthanatos-related
disorders and reveal unexpectedly PD98059 as an effective parthanatos-
alleviating compound that should guide the future direction for drug
development.
2. Materials and methods
2.1. Reagents and antibodies
MNNG (O-2392) was purchased from Chem Service. 7-
Aminoactinomycin D (7AAD, 559925) was obtained from BD
Pharmingen. zVAD-fmk (219007), doxorubicin (324380), SB203580
(559389), SP600125 (420119), U0126 (662005), PD98059 (513000),
wortmannin (681675), and compound C (171260) were ordered from
Calbiochem. Gallotannin (403040), rapamycin (R8781), baﬁlomycin
A1 (B1793), rotenone (R8875), diphenyliodonium (DPI, D2926),
triﬂuorocarbonylcyanide phenylhydrazone (FCCP, C2920), MTT
(M2128) andDulbecco's PBS (D5652)were obtained fromSigma-Aldrich.
JC-1 (T3168), Dulbecco's Modiﬁed Eagle Medium (DMEM, 12100-046),
trypsin-EDTA (25200-072), fetal bovine serum (FBS, 04001-1A), and
penicillin/streptomycin (03031-1B) were purchased from Invitrogen.
The FastStart Universal SYBR Green Master (14526100) was ordered
from Roche Applied Science. Commercial antibodies against p-ERK1/2(Thr202/Tyr204, 9101), p-JNK (Thr183/Tyr185, 9251), p-p38 (Thr180/
Tyr182, 9211), p53 (9282), p-AMPKα1 (Thr172, 2531), AMPKα1
(2532), p-GSK3β (Ser9, 9336), p-Akt (Ser473, 9271), Akt (9272), and
SQSTM1/p62 (5114) were purchased from Cell Signaling Technology
(Beverly, MA, USA); GSK3β (sc-9166), ERK1/2 (sc-292838), JNK1
(sc-474), and p38 (sc-7149) were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA); Atg5 antibody (ab54033-100) was purchased
from Abcam; β-actin antibody (MAB1501) was purchased from
Upstate Biotechnology; PAR antibody (551813) was purchased
from BD Pharmigen; γH2AX antibody (05-636) was ordered from
Merck Millipore; LC3 antibody (PM036) was purchased from
MBL. Normal rabbit IgG and horseradish peroxidase-conjugated anti-
bodies (sc-2004) were purchased from Santa Cruz Biotechnology.
Enhanced chemiluminescence (ECL) reagent was ordered from Perkin
Elmer.
2.2. Cell culture
Atg5+/+ and Atg5−/− MEFs were kindly provided by Dr. Noburu
Mizushima (Tokyo Medical and Dental University). Primary WT and
PARP1−/−MEFs were isolated from fresh 129S WT and 129S PARP1−/−
mice, respectively. HeLa cells were purchased from the American Type
Culture Collection (Manassas, VA, USA). MEFs and HeLa cells were
cultured in high-glucose DMEM supplemented with 10% heat-
inactivated FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. The
cells were incubated at 37 °C in a humidiﬁed atmosphere with 5% CO2.
2.3. Intracellular ATP assay
Intracellular ATPwas determined by CellTiter-Glo® Luminescent Kit
(G7571) from Promega according to the manufacturer's protocol. In
brief, 5 × 104 cells were seeded per well in a 24-well plate for 24 h
followed by the treatment indicated. Medium was then replaced with
the new one, and the reagent was added to lyze the cells. The plate
was gently shaken for 2 min, placed stationary in the dark for 10 min,
and then 150 μl solutionwas transferred to a 96-well plate for lumines-
cence detection using LB96V MicroLumat Plus (American Laboratory
Trading). With background subtraction, the values were normalized to
individual control group as 100%.
2.4. Determination for 7AAD+ cells
MEFswere seeded in a 24-well plate (5 × 104 cells perwell) for 24 h
followed by the treatment indicated. The supernatant was collected,
and the cells were trypsinized and then mixed with the respective
supernatant, followed by centrifugation at 2500 rpm for 10 min at
room temperature. The pelleted cells were washed with 1× PBS
once and then centrifuged in a similar manner. Then, the cells
were resuspended with PBS containing 7AAD (5 μM) and then
submitted to FACS analysis (FACScan ﬂow cytometer, Becton
Dickinson) using the CellQuest program. The data were obtained
based on the FL3 channel.
2.5. Lactate dehydrogenase (LDH) release assay
LDH release assaywas performedusing CytoTox 96®Non-Radioactive
Cytotoxicity Assay Kit (G1780) from Promega according to the man-
ufacturer's protocol. In brief, cells were seeded in a 24-well plate
(5 × 104 cells perwell) for 24 h followed by the treatment as indicated.
The readout for the maximum LDH release was achieved by Lysis
Solution (10×) 45 min before the endpoint. The supernatant from
each well was collected and centrifuged for 5 min at 4 °C, and then
transferred in 50 μl into a 96-well plate, followed by 50 μl reconstituted
substrate mix, for a desired incubation period (protected from light).
A ﬁnal 50 μl stop solution was added into each well, and the plate was
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represented by the complete lysis group as 100%.
2.6. Immunoblot
Cells were lyzed with the RIPA buffer supplemented with a cocktail
of proteinase inhibitors. After sonication, protein concentrations were
determined using the Bio-Rad protein assay. Each sample with the
equal protein concentration was electrophoresed on SDS-PAGE, and
transferred to the PVDF membranes. Nonspeciﬁc binding was blocked
with 5% nonfat milk. After immunoblotted with the primary speciﬁc
antibodies as indicated, membranes were washed and incubated
with an HRP-conjugated secondary antibody. Protein bands were
detected with an enhanced chemiluminescence detection reagent.
The signals were quantiﬁed by ImageJ 1.48 g with suitable back-
ground calibration and represented as indicated the ratio of respec-
tive intensity units.
2.7. Immunoprecipitation for SIRT1 activity assay
SIRT1 activity was measured by CycLex Sir2 Assay Kit (CY-1151)
from MBL International Corporation according to the manufacturer's
protocol. In brief, after SIRT1 immunoprecipitation, a mixture of SIRT1
reaction agents was added and incubated for 1 h. Finally, 50 μl superna-
tant per sample was transferred into a 96-well dark plate, followed by
50 μl 2× Stop Solution. At this time, a blank (Cell Lysis Buffer alone)
and a recombinant SIRT1 were used as background correction. Fluores-
cence was read by LB96V MicroLumat Plus with excitation wavelength
at 340–360 nm and emission at 440–460 nm. Data were normalized
to the protein content measured by Bradford method and expressed
as % compared to the WT control group (100%).
2.8. Mitochondrial DNA (mtDNA) quantiﬁcation
After drug treatment, the cell pellet was added with UniversALL™
Extraction Buffer (Yeastern, Cat. YGF10-1) and heated for 10 min at
95 °C for complete extraction of total DNA, and DNA concentration
was quantiﬁed by the LB96V MicroLumat Plus at 260 nm and 280 nm.
A total of 1 μg DNA was used, mixed well with the FastStart SYBR
Green Master (Roche), and then submitted to quantitative real-time
PCR analysis with automatic CT setting, with a program of 20 min at
95 °C, followed by 50 cycles for 15 s at 95 °C, 20 s at 58 °C and 20 s at
72 °C. Single-product ampliﬁcation was veriﬁed by an integrated post-
runmelting curve analysis. The primer sequence pairs used for quantita-
tive real-time PCR were mtDNA (16S rRNA) forward 5′-AGCTG AAGAA
AGCGT GTTCC A-3′, mtDNA (16S rRNA) reverse 5′-AACTC TGTCC
AAGAT CGCTG ACT-3′, nuclear DNA (hexokinase 2, intron 9) forward
5′-CGGGG ACCTG ACTGA CTACC-3′ and nuclear DNA (hexokinase 2,
intron 9) reverse 5′-AGGAA GGCTG GAAGA GTGC-3′. mtDNA content
was calculated from the difference in CT values between mtDNA and
nucleus-speciﬁc DNA and expressed as fold increase based on a 2−△△CT
method.
2.9. RNA extraction, reverse transcription, and quantitative real-time PCR
RNA extraction and real time-PCR were conducted as we previously
described [26]. The primer sequence pairs used for quantitative real-
time PCR were PGC1α forward 5′-AGCCGTGACCACTGACAACGAG-3′,
PGC1α reverse 5′-GCTGC ATGGT TCTGAGTGCT AAG-3′; β-actin forward
5′-CGGGG ACCTG ACTGA CTACC-3′, β-actin reverse 5′-AGGAA GGCTG
GAAGA GTGC-3′.
2.10. MTT assay
MEFs (5 × 104 per well) were seeded in a 24-well plate for 24 h
followed by the treatment as indicated. At the endpoint, MTT solution(5 mg/ml) was added into the medium per well with a 5-fold dilution,
and the plate was incubated for 1 h at 37 °C. After that, the solution
was aspirated, and the purple formazan granules metabolized by the
mitochondria in live cells were resolved with 300 μl DMSO. The signal
was detected by LB96V MicroLumat Plus (American Laboratory
Trading) at 550 and 630 nm. Data were represented by A550–630 and
normalized with the individual control group as 100%.
2.11. Determination for mitochondrial transmembrane potential
(MTP, △Ψm)
JC-1 dye was used to detect△Ψm by FACS analysis. If△Ψm is main-
tained, JC-1 forms as a dimer and reveals red; otherwise, when△Ψm is
disrupted, JC-1 acts as a monomer and the red color declines into an
orange or yellow color. Of note, additional rotenone-treated and
FCCP-treated groups were used as positive controls. After drug
treatment, medium was aspirated, replaced with PBS containing
JC-1 (5 μg/ml) for 30 min at 37 °C in the dark. The cells were then
trypsinized and transferred into a micro-centrifuge tube, centrifuged
at 2500 rpm for 10 min, resuspended as a single-cell suspension,
followed by FACS analysis (FACScan ﬂow cytometer, Becton Dickinson)
using the CellQuest program. The data were obtained based on the
FL1 (on the x-axis) and FL2 (on the y-axis) channels with appropriate
compensation, and expressed as the cell percentage with signiﬁcant
loss of FL-2 signal under the user-deﬁned quadrant analysis.
2.12. Statistical analysis
All statistical analyses were performed with unpaired two-tailed
Student's t-tests. Values were expressed as the mean ± S.E.M. from at
least three independent experiments, each of which was done in 2–3
replicates.
3. Results
3.1. Atg5−/−MEFs are vulnerable to MNNG-induced cell death
The parthanatos inducer MNNG triggered the ATP depletion within
4 h treatment followed by a recovery phase in MEFs, where Atg5−/−
MEFs showed impaired ATP restoration compared to the WT counter-
part (Fig. 1A). Similar to our previously work demonstrating that
MNNG-induced PARylation and necrotic cell death in MEFs could be
abrogated by the pharmacological inhibitors 3AB and/or DPQ [7], we
also conﬁrmed this notion in terms of ATP depletion. Our data revealed
that MNNG-induced early-phase ATP depletion could be completely
abrogated by the PARP1 inhibitor 3AB (Fig. 1B) or in the absence of
PARP1 (Fig. 1C). In support of necrotic context, MNNG-elicited ATP
dynamic alteration was not affected in the presence of pan-caspase
inhibitor zVAD-fmk (Fig. 1D). Consistent with the fragility in
MNNG-treated Atg5−/− MEFs, LDH release was detectable at 9 h
and up to 60% at 24 h (Fig. 1E). Similarly, by use of 7AAD, which
could intercalate double-stranded nucleic acids from dying and
dead cells, we demonstrated that Atg5−/−MEFs showed more 7AAD+
signals in response toMNNG than theWT counterpart (Fig. 1F). Further-
more, we conﬁrmed this biphasic ATP alteration is speciﬁc to MNNG in
MEFs, where both WT and Atg5−/− MEFs similarly responded to the
topoisomerase inhibitors doxorubicin (Fig. 1G) and etoposide (Fig. 1H).
Taken together, these data suggest that Atg5−/− MEFs are vulnerable
to MNNG-induced cell death with disabled ATP recovery.
3.2. MAPKs do not regulate energy adaptive response during parthanatos
in MEFs
As previouslymentioned in other contexts [13,14], we alsowondered
whether MAPKs have a role in energy adaptation during parthanatos in
MEFs. Phosphorylation of ERK, JNK and p38 was similarly induced in
Fig. 1. Atg5−/−MEFs are susceptible to parthanatos with disabled ATP restorability. (A, B, D) Intracellular ATP content after 150 μMMNNG administration at indicated time points was
determined in Atg5+/+ and Atg5−/− paired MEFs in the absence or presence of 10 μM 3AB (B) or 20 μM zVAD-fmk (D) pretreated for 30 min. (C) Intracellular ATP content after
150 μMMNNGadministration at indicated time pointswas determined inprimaryWT andPARP1−/−MEFs isolated from fresh 129SWTand PARP1−/−mice, respectively. (E) LDH release
after 150 μMMNNG administration at indicated time points was measured inWT and Atg5−/−MEFs. (F) FACS analysis of cell death was performed inMEFs treated with 150 or 300 μM
MNNG for 24 h, where 5 μM 7AADwas incubated 30 min prior to FACS. (G, H) Intracellular ATP content after 3 μM doxorubicin (DXR) administration (G), and intracellular ATP content
andMTT activity after 100 or 200 μM etoposide administration (H) at indicated time points were determined inWT and Atg5−/−MEFs. Signiﬁcance level: *p b 0.05 compared to theWT
counterpart in the same treatment and time point.
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SB203580 (a p38 inhibitor) (Fig. 2B), SP600125 (a JNK inhibitor)
(Fig. 2C) and U0126 (a MEK/ERK inhibitor) (Fig. 2D) did neither affect
nor explain the differential ATP alteration in WT and Atg5−/− MEFs
during parthanatos. Therefore, despite their participation in other
parthanatic contexts, MAPKs do not regulate the ATP adaptive response
in these MEFs. Additionally, administration of either necrostatin-1
(a RIP1 inhibitor), BAPTA/AM (a cytosolic calcium chelator), or CA-074(a cathepsin B inhibitor) did not interfere with MNNG-elicited ATP
dynamic responses in both WT and Atg5−/−MEFs (Fig. 2E).
3.3. PD98059 effectively facilitates ATP restoration during parthanatos and
saves vulnerable MEFs in a MEK-independent manner
In the aboveMAPKscreen,wediscoveredunexpectedly that PD98059,
a ﬂavonoid derivative considered the conventional MEK/ERK inhibitor,
Fig. 2.MAPKs do not regulate energy adaptive response during parthanatos inMEFs. (A) Immunoblot analysis of theMAPK-related proteins inWT andAtg5−/−MEFs after 150 μMMNNG
challenge at indicated time points. The bands representative of Atg5 were shown as Atg12-conjugated forms. (B–E) Intracellular ATP content after 150 μMMNNG administration at
indicated time points was determined in WT and Atg5−/−MEFs in the presence or absence of 3 μM SB203580 (B), 30 μM SP600125 (C), 3 μM U0126 (D), 10 μM necrostatin-1, 10 μM
BAPTA/AM, or 10 μM CA-074 (E). In each row of quantitative results regarding immunoblots, the normalized reference was framed as indicated.
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and dampened cell death (Fig. 3B) in response toMNNG evidently in vul-
nerable Atg5−/− MEFs at the concentration as low as 3 μM. Notably,
MNNG-induced ERK1/2 phosphorylation was not attenuated byPD98059 at 10 μM, neither JNK nor p38 phosphorylation (Fig. 3C
and D). Notably, inhibition of ERK phosphorylation could be readily
achieved by U0126 at 3 μM (Fig. 3C), while only partially achieved
by PD98059 at 30 μM (Fig. 3D). Furthermore, post-treatment of
Fig. 3. PD98059 effectively facilitates ATP restoration during parthanatos and saves vulnerable MEFs independently of MEK inhibition. Intracellular ATP content (A) and LDH
release (B) after 150 μMMNNG administration at indicated time points were determined in WT and Atg5−/−MEFs in the presence or absence of PD98059 at 3, 10, or 30 μM
pretreated for 30 min. (C) Immunoblot analysis of ERK phosphorylation was conducted inWT and Atg5−/−MEFs after 150 μMMNNG challenge at indicated time points in the
presence or absence of 10 μMPD98059 (top panel) or 3 μMU0126 (bottom panel), pretreated for 30 min. (D) Immunoblot analysis of the indicated proteins was conducted in
WTMEFs after 150 μMMNNG challenge at indicated time points in the presence or absence of PD98059 at 10 or 30 μMpretreated for 30 min. (E) Intracellular ATP content was
determined in WT and Atg5−/−MEFs in the presence or absence of 10 μM PD98059 pre-treated for 30 min or post-treated at 1 or 4 h after 150 μMMNNG administration at
indicated time points. In each row of quantitative results regarding immunoblots, the normalized reference was framed as indicated.
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the similar protectiveness as pre-treatment (Fig. 3E). Collectively,
these data implied PD98059 as an effective parthanatos-inhibiting
compound whose protectiveness is through a MEK-independent
mechanism.Fig. 4. PD98059 protects MNNG-treated MEFs without modulation on DNA damage response
performed in WT (A–D) and Atg5−/−MEFs (B, C) after 150 μMMNNG challenge at indicated
U0126 (C), pretreated for 30 min. (E) Intracellular ATP content after 150 μMMNNG administr
or absence of 10 μM PD98059 and/or 30 μMgallotannin (GLTN), pretreated for 30 min. In each
as indicated. PAR-PARP1 indicates PARylated PARP1.3.4. PD98059 protects MNNG-treated MEFs without modulation on DNA
damage responses
We questioned whether protection by PD98059 at effective dosage
against parthanatos comes from modulation of MNNG-elicited PARP1s. (A–D) Immunoblot analyses of PARylated PARP1 (A, B), p53 (C), and γH2AX (D) were
time points in the presence or absence of 10 μM (B, C) or 30 μM (A) PD98059, or 3 μM
ation at indicated time points was determined in WT and Atg5−/−MEFs in the presence
row of quantitative results regarding immunoblots, the normalized reference was framed
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ﬁrst determined PARP1-dependent PARylation as an index of PARP1
activity. Administration of MNNG rapidly induced PARylation of several
proteins, especially with the apparent effect on protein(s) at the same
molecular weight as PARP1 (113 kD) (Fig. 4A and B). As PARP1 itself
can undergo PARylation [27], this obvious PARylation signal might be
representative of PARP1 and its activity. Importantly, we found that
PARP1 PARylation following MNNG treatment was unaffected in the
presence of PD98059 in both WT and Atg5−/− MEFs, albeit a higher
PAR signal was noted in Atg5−/−MEFs (Fig. 4B). This PARP1 PARylation
after MNNG treatment was neither signiﬁcantly affected by PD98059 at
higher concentration (30 μM) when ERK inhibition was achieved
(Fig. 4A). Next, to further evaluate if PD98059 might affect MNNG-
induced DNA damage responses, we determined p53 and γH2AX
expression. We found that MNNG-induced p53 protein expression in
both WT and Atg5–/− MEFs was neither disturbed by PD98059 nor
U0126 (Fig. 4C) and ditto for γH2AX expression in WT MEFs (Fig. 4D).
To test whether PD98059 could still be protective under enhanced
death signal, we utilized the poly(ADP-ribose) glycohydrolase (PARG)
inhibitor gallotannin (GLTN) for PAR retention. Within 8 h screening,
ATP restoration following MNNG treatment was signiﬁcantly impaired
in the presence of GLTN in bothMEFs, while addition of PD98059 in con-
text with GLTN still facilitated ATP recovery in both WT and Atg5−/−
MEFs (Fig. 4E). Therefore, these data argue that PD98059 protects
MEFs from parthanatos without modulation on DNA damage responses.
3.5. AMPK is indispensable to energy adaptation during parthanatos
Since the energy stress is a clear signature of parthanatos, we turned
to examine other master stress kinases about their contribution to
parthanatic energy responses in MEFs. Western blot analysis demon-
strated that phosphorylation of AMPKα1 at Thr172 was induced as
early as 30 min after MNNG administration in MEFs, but faded down
thereafter (Fig. 5A). Here, we noted a higher basal AMPKα1 phosphor-
ylation in Atg5−/−MEFs. Within 30 min challenge, the levels of phos-
phorylation on Akt at Ser473 and GSK3β at Ser9 decreased whenever
AMPK was active (Fig. 5A), suggesting a reciprocal activation relation-
ship between AMPK and Akt/GSK3β signal pathways immediately
after MNNG administration. After this early inhibitory response, the
Akt and GSK3β phosphorylation statuses concordantly rebounded
(Fig. 5A). However, in the presence of PD98059, the phosphorylation
dynamics of these kinases inducible by MNNG was not signiﬁcantly
affected in both MEFs (Fig. 5A). To understand the essential role of
AMPK in energy regulation upon parthanatos, we used the pharmaco-
logic AMPK inhibitor compoundC. Indeed, in the presence of compound
C, the ATP restorability during parthanatos was both impaired in WT
and Atg5−/− MEFs (Fig. 5B). Remarkably, addition of PD98059 still
facilitated ATP recovery in MNNG-challenged WT and Atg5−/−MEFs in
the presence of compound C (Fig. 5B). On the other hand, pharmacologic
inhibition of PI3K/Akt by wortmannin or mTORC1 by rapamycin only
slightly worsened the energy restoration in MNNG-treated Atg5−/−
MEFs, not comparable to that caused by compound C (Fig. 5C). Consis-
tently, LDH releasewas aggravated in bothMEFs by compoundC,where-
as addition of PD98059 alleviated this aggravation (Fig. 5D). Conjointly,
these data indicate that AMPK is a vital kinase for cells against energy
deprivation and cytotoxicity during parthanatos.
3.6. Diminished mitochondrial activity in Atg5−/− MEFs in response
to parthanatos
Considering the versatility of AMPK, we ﬁrst intuitively tested
whether mitochondrial signaling and activity are an inevitable part of
AMPK-mediated cytoprotective effects against parthanatos via SIRT1
and mitochondrial biogenesis [28]. At 8 h after MNNG administration,
when the ATP level in WT MEFs was ready for a signiﬁcant rebound
yet not in Atg5−/−MEFs (Fig. 1A), we consistently observed that SIRT1activity was rather impaired in Atg5−/−MEFs but not signiﬁcantly af-
fected in WT counterpart (Fig. 6A). We also noted here that Atg5−/−
MEFs harbored an inherently compromised SIRT1 activity at basal
level (about 80% compared to WT; Fig. 6A). However, with addition
of PD98059, SIRT1 activity was signiﬁcantly elevated in both MNNG-
challenged WT and Atg5−/−MEFs (Fig. 6A). In line with the necessity
of SIRT1, pharmacologic inhibition of SIRT1 by sirtinol completely
ampliﬁed MNNG cytotoxicity in both WT and Atg5−/−MEFs (Fig. 6B).
With a check in mitochondrial DNA (mtDNA) content, however, we
found that MNNG was able to increase mtDNA content at 1 h in both
WT and Atg5−/− MEFs, but the intensity was attenuated thereafter
(Fig. 6C). Besides, a higher mtDNA induction was noted in Atg5−/−
MEFs than in the WT counterpart in response to MNNG (Fig. 6C). We
reasoned that this compensatory higher burst was reﬂective of intrinsic
deﬁciencies in mitochondrial quality control in Atg5−/− MEFs, even
though it was still not comparable for providing sufﬁcient energy
resources from these defective mitochondria during parthanatos. In
the presence of PD98059, we observed that a higher induction fold
and a longer retention intensity of mtDNA content were achieved in
both WT and Atg5−/−MEFs after MNNG challenge (Fig. 6C). Further-
more, we also noticed that, in both WT and Atg5−/− MEFs, PD98059
alone was capable of stimulating mtDNA synthesis (Fig. 6C) and raising
the transcription of peroxisome proliferator-activated receptor (PPAR)
gamma coactivator 1 alpha (PGC1α) (Fig. 6D), whose product is a mas-
ter regulator of mitochondrial gene expression and energy metabolism
[29].
To further conﬁrm the mitochondrial setting for energy restoration
afterMNNG challenge,we used themitochondrial pharmacologic inhib-
itors rotenone (a complex I/II inhibitor), DPI (a ﬂavoprotein inhibitor),
and FCCP (a mitochondrial uncoupler). In the presence of rotenone,
DPI or FCCP, MNNG cytotoxicity was extremely exasperated in both
WT and Atg5−/− MEFs (Fig. 6E). Of note, all of these mitochondrial
inhibitors alone did not lead to differential energy level between WT
and Atg5−/−MEFs at 24 h treatment (Fig. 6E). For a close view about
the ATP-depleting process, we found that the ATP level was severely
exhausted in the presence of rotenone or DPI in both WT and Atg5−/−
MEFs as early as 15 min after MNNG challenge andwithout subsequent
rebound (Fig. 6F). On the other hand, we also utilized the MTT, a tetra-
zolium dye which could be converted into a purple formazan by the
mitochondrial succinate dehydrogenase in viable cells as an indicator
of mitochondrial activity. Concordantly, MNNG challenge decreased
MTT activity to higher extent in Atg5−/−MEFs than in theWT counter-
part (Fig. 6G). In 1 h MNNG treatment, the MTT activities were equally
suppressed to half their basal levels, but thereafter, this compromised
mitochondrial activity was relieved in WT MEFs while continuously
suppressed in Atg5−/−MEFs (Fig. 6G). Moreover, addition of PD98059
better recovered mitochondrial activity in Atg5−/− MEFs 10 h after
MNNG administration, but not signiﬁcantly improved further in WT
MEFs (Fig. 6G). To determine whether necrotic events preceded the
early suppression of ATP level and mitochondrial activity, we used the
JC-1 dye to evaluate the mitochondrial transmembrane potential
(△Ψm), whose dissipation is a common signature of mitochondrial
depolarization in necrotic cell death. Intriguingly, △Ψm dissipation
was undetectable at 1, 4, and 8 h after MNNG challenge in both WT
and Atg5−/− MEFs (Fig. 6H), yet the validity of experiment was
conﬁrmed by the positive controls using FCCP and rotenonewith detect-
able dissipation occurring as early as in 4 h treatment in Atg5−/−MEFs
(Fig. 6H). Collectively, these results suggest that mitochondrial activity
predetermines the tolerability of cells to MNNG and unveil its dimin-
ished activity in Atg5−/−MEFs during parthanatos.
3.7. Autophagic ﬂux is not obligatory for energy supply and protection
during parthanatos
With observations on a requirement of AMPK in energy adaptation
and the susceptibility of Atg5−/− MEFs, together with the notion for
Fig. 5. AMPK is indispensable to energy adaptation during parthanatos. (A) Immunoblot analysis of major stress response-related proteins was conducted inWT and Atg5−/−MEFs after
150 μMMNNG challenge at indicated time points in the presence or absence of 10 μMPD98059 pretreated for 30 min. (B, C) Intracellular ATP content after 150 μMMNNGadministration
at indicated time points was determined inWT and Atg5−/−MEFs in the presence or absence of 10 μMcompound C (CC) and/or 10 μMPD98059 (B), 100 nMwortmannin (C, top panel),
or 100 nM rapamycin (C, bottom panel), respectively, pretreated for 30 min. (D) LDH release after 150 μMMNNG administration at indicated time points was measured inWT
and Atg5−/−MEFs in the presence or absence of 10 μM compound C and/or 10 μM PD98059, pretreated for 30 min. In each row of quantitative results regarding immunoblots,
the normalized reference was framed as indicated. Signiﬁcance level: *p b 0.05.
539C.-T. Huang et al. / Biochimica et Biophysica Acta 1843 (2014) 531–543
Fig. 6. Atg5−/−MEFs reveal diminished mitochondrial activity essential to surviving parthanatos. (A) SIRT1 activity was determined inWT and Atg5−/−MEFs 8 h after 150 μMMNNG and/or
10 μM PD98059 administration, pretreated for 30 min if necessary. (B) Intracellular ATP content after 150 or 300 μMMNNG administration at 24 h was determined inWT and Atg5−/−MEFs
in the presence or absence of 50 μM sirtinol pretreated for 30 min. (C) Mitochondrial DNA (mtDNA) content was determined after 150 μMMNNG and/or 10 μM PD98059 administration at
indicated time points in WT and Atg5−/− MEFs, pretreated for 30 min if necessary. (D) PGC1α transcripts following 10 μM PD98059 at indicated time points were measured in WT
and Atg5−/−MEFs. (E) Intracellular ATP content 24 h after 150 μMMNNG administration was determined in WT and Atg5−/−MEFs in the presence or absence of 500 nM rotenone
(Ro), 10 μM DPI, or 30 μM FCCP, pretreated for 30 min if necessary. (F) Intracellular ATP content after 150 μMMNNG administration at indicated time points was determined in WT and
Atg5−/−MEFs in the presence or absence of 500 nM rotenone (top panel) or 30 μM DPI (bottom panel) pretreated for 30 min. (G) MTT activity after 150 μMMNNG administration at
indicated time pointswas determined inWT andAtg5−/−MEFs in the presence or absenceof 10 μMPD98059pretreated for 30 min. (H) Integrity ofmitochondrial transmembranepotential
(△Ψm) after 150 μMMNNG administration at indicated time points was determined in WT and Atg5−/−MEFs. The validity of experiment was conﬁrmed by 30 μM FCCP and 500 nM
rotenone as positive controls in Atg5−/−MEFs. ND, not determined. Signiﬁcance level: *p b 0.05 compared to the individual DMSO control groups. #p b 0.05 compared to the individual
MNNG challenge groups at the same time point.
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speculated a role of autophagy during parthanatos. In the presence
of baﬁlomycin A1, a vacuolar H+ ATPase inhibitor that prevents
autolysosomal fusion, we found, however, that MNNG did not promote
LC3 lipidation, a molecular signature of autophagosome maturation.
Consistently MNNG did not induce p62 degradation, a consequence of
cargo elimination within autolysosomal compartment, in WT MEFs
without baﬁlomycin A1 treatment. Noticeably, the defective autophagy
induction machinery in Atg5−/− MEFs was conﬁrmed by the absence
of lipidated (LC3-II) and the p62 accumulation (Fig. 7A). Consistently,wedid neither observe LC3 lipidation inHeLa cells afterMNNG challenge
(Fig. 7B), while a gradual decline in expression of LC3-II was noted
(Fig. 7B). Much strikingly, MNNG-mediated ATP response curves and cy-
totoxicity were not exacerbated in the presence of baﬁlomycin A1 in
both WT and Atg5−/−MEFs (Figs. 7C and D). Compatibly with above,
the addition of PD98059 still facilitated ATP recovery in WT and Atg5
−/−MEFs in the presence of baﬁlomycin A1 after MNNG administration
(Fig. 7E). Therefore, these results together with Fig. 6 indicate that
parthanatos does not induce autophagic ﬂux but is aggravated by the
deﬁcits in mitochondrial quality control underlying Atg5 deﬁciency.
Fig. 7. Autophagic ﬂux is not obligatory for energy supply and protection during parthanatos. (A, B) Immunoblot analyses of autophagic ﬂux-related proteins were conducted in WT
and Atg5−/−MEFs (A) and in HeLa cells (B) after 150 μMMNNG and/or 100 nM baﬁlomycin A1 (baf A1) administration at indicated time points, pretreated for 30 min if necessary.
(C–E) Intracellular ATP content (C, E) and LDH release (D) after 150 μMMNNG, 100 nM baﬁlomycin A1 (baf A1), and/or 10 μM PD98059 administration at indicated time points in
WT and Atg5−/−MEFs, pretreated for 30 min if necessary. In some rows of quantitative results regarding immunoblots, the normalized reference was framed as indicated if necessary.
541C.-T. Huang et al. / Biochimica et Biophysica Acta 1843 (2014) 531–5434. Discussion
Massive NAD+ and ATP depletion is a general mark of PARP1-
mediated necrotic cell death. Despite the current progress that exogenous
supplementation of metabolic intermediates could save neurons or glia
cells from PARP1-mediated cell death [15,16,31,32], less is known about
the regulation of energy turnover during the parthanatos. Here, we char-
acterized the depleting and recovering phases of ATP level during
parthanatos and underscored the recovery capability as a determinant
of severity of parthanatic cell death. By using macroautophagy-defective
Atg5−/−MEFs, we highlighted their extraordinary vulnerability to the
alkylating agent MNNG, but not to the DNA-intercalating topoisomerase
II inhibitors doxorubicin and etoposide, which could potently initiate
apoptotic cell death [33]. Regarding a potential dual role of Atg5 in
autophagy and apoptosis [34], our observed fragility and impaired
ATP restorability of Atg5−/− MEFs to MNNG were unaffected by the
pan-caspase inhibitor zVAD-fmk, together with the unequivocally similar
responses of WT and Atg5−/−MEFs to doxorubicin suggesting that Atg5
deﬁciency confers a speciﬁc inﬁrmity to parthanatos.Our ﬁndings indicate that the MAPK signaling pathways are not
involved in the regulation of parthanatic energy responses, albeit their
reported modalities elsewhere to DNA repair, cell cycle arrest, and
defense response to stress [13,14,35,36]. Furthermore, both WT and
Atg5−/−MEFs showed comparableMAPK activation during parthanatos,
possibly excluding a link underlying Atg5 deﬁciency to those activation.
A MEK-independent PD98059 protectiveness from parthanatos is
exceptionally highlighted throughout this study. The differential actions
between the conventional MEK kinase inhibitors PD98059 and U0126
have been reported somewhere in literature, where, for example,
PD98059 could potently stimulate adipogenesis but U0126 did not [37].
In line with their ﬁndings, here we also showed that only PD98059
administration effectively saved MEFs from parthanatos. Indeed, several
MEK-independent actions for PD98059 have been reported and might
be correlated to its property as a ﬂavonoid derivative, including weak
estrogenic activity [37,38], elevation of glutathione [39–41], andbehaving
as an aryl hydrocarbon receptor (AHR) antagonist [42]. Notably, in this
study we implied that PD98059 protectiveness from parthanatos comes
from an enhancement of mitochondrial activity, without modulation on
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with previous ﬁndings [37,38] and a body of knowledge that links
estrogenic activities to mitochondrial respiration [43–45], we believe
that PD98059 is able to boost up mitochondrial functionality which
seems extremely essential to energy restoration during parthanatos.
AMPK is a multifunctional protein kinase that participates in energy
expenditure and autophagy induction in response to diverse stimuli
[30,46]. In this study we uncovered an absolute requirement of AMPK
to protect cells from parthanatos and dissected its potential down-
stream cellular processes [28,47,48], i.e., underlining the importance of
mitochondrial metabolism but, unexpectedly, not of autophagy induc-
tion as an adaptive response to parthanatos. The unnecessariness of
autophagic ﬂux machinery for energy restoration during parthanatos
was also exempliﬁed in our study by the absence of LC3 lipidation and
p62 elimination after MNNG challenge, the parthanatos irresponsive
to baﬁlomycin A1, as well as parthanatos insensitive to enforced
autophagy induction by mTORC1 inhibition, which is supposed to be
responsible for autophagy induction downstream of AMPK activation
[49]. Furthermore, the PD98059 protectiveness was also rechecked to
be independent of autophagy induction as illustrated with its effective-
ness in the presence of baﬁlomycin A1. In this study, we also observed
the higher basal AMPK signaling in Atg5−/− MEFs. We reasoned that
the increased AMPK activity might be the compensatory adaptation in
Atg5−/− MEFs. However, an alternative macroautophagy has also
been reported in Atg5−/−MEFs in response to starvation or etoposide
[50], but here we precisely excluded the need of autophagy ﬂux in
parthanatos by use of the autophagy inhibitor baﬁlomycin A1, which
shall block all the autophagic clearance events.
After ruling out the necessity of autophagic ﬂux in restoringmitochon-
drial activity and subsequent energy level during parthanatos, we rea-
soned that it is deﬁcits in mitochondrial quality control associated with
Atg5 knockout [51,52] that contribute to impaired mitochondrial energy
adaptability in response to this stress. In other setting, Stephenson et al.
have shown that Atg5-dependent transcriptional changes were enriched
in genes associated with mitochondrial maintenance by analyzing differ-
entially expressed genes betweenWT and Atg5−/− thymocytes [53]. Con-
sistently here, we demonstrated that Atg5−/−MEFs harbored an inherent
diminishment inmitochondrial activitywhich is required for energy resto-
ration and explainable for the vulnerability during parthanatos. Despite
the currently unknown higher AMPKα1 phosphorylation status and the
stronger mtDNA induction fold observed in our study, Atg5−/− MEFs
were still unable towell survive parthanatos owing to their intrinsic mito-
chondrial inadequacy. Even though PD98059 could dose-dependently and
effectively recover ATP level in Atg5−/−MEFs during parthanatos, this
rescue was not comparable to the WT counterpart similarly due to their
mitochondrial defects.
Both SIRT1 and PARP1 consume NAD+ to perform their major action,
deacetylation and poly(ADP-ribosyl)ation, respectively [54], and the
functional interplay between them has also been documented. For
instance, PARP1 over-activation was associated with subsequently
reduced SIRT1 deacetylase activity leading to myocyte cell death during
heart failure [55]. On the contrary, activation of SIRT1 dampened
poly(ADP-ribose) polymerase activity of PARP1whereas SIRT1 deﬁciency
ampliﬁed PAR synthesis [56]. Furthermore, direct interaction between
PARP1 and SIRT1 is also possible, such as SIRT1-dependent deacetylation
on PARP1 to block PARP1 activity [57]. In this context, our data also sup-
port an inherent PARP1/SIRT1 imbalance in Atg5−/− MEFs with an
enhanced PAR signal and a decreased SIRT1 activity at the basal level,
which may underlie their vulnerability to MNNG. Interestingly, we also
observed that, in the presence of the PARP1 inhibitor 3AB or the absence
of PARP1, administration of MNNG actually triggers an initial ATP burst
exceeding the basal level within 8 h treatment. We reasoned that,
under PARP1 inhibition when alkylated DNAs are still unresolved, a
PARP1-independent machinery continues to operate, accounting for
this surplus of ATP. Consistentlywith this phenomenon, PARP1 inhibition
could increase mitochondrial content and energy expenditure throughSIRT1 activation, rendering protection against several metabolic diseases
as well as cancer [58]. However, considering the versatility and broad
participation of SIRT1 andPARP1under several physiologic andpatholog-
ic conditions [17,59,60], the background metabolic status underlying
SIRT1/PARP1 imbalance in Atg5−/−MEFs is worthy of investigation to a
greater extent, which may help clarify the interrelationship among
SIRT1, PARP1, and macroautophagy, and beneﬁt the treatment of many
disorders linking to dysregulation in these aspects.
Our results provide a complete energy perspective dealing with its
regulation on theparthanatic response and explicitly point out the ener-
gy status as a key determinant in the death outcome. PARP1-mediated
cell death has been frequently described in type I diabetes [10], in
neuropathology such as stroke [61], excitotoxicity [61,62], and neurode-
generation [12,21], aswell as at necrotic loci from ischemia–reperfusion
injury likemyocardial infarcts [63]. Concomitantly, autophagy dysregu-
lation has also been implicated in these neurological and cardiovascular
diseases [25,64,65]. In contrast, we clarify in this study a link of
mitochondrial quality maintained by autophagy to the severity of
parthanatos. Moreover, concerning the urgent need of efﬁcacious
PARP inhibitors for better therapeutic beneﬁts within a wide range of
inﬂammatory disorders [17], we also identify unexpectedly PD98059
as a cytoprotective compound against parthanatos via enhancing
mitochondrial metabolism and facilitating energy restoration following
the ATP depletion. Taken together, our ﬁndings establish a fundamental
basis for treating these parthanatos-related disorders and should guide
the future direction for drug development.
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